Merlin Nexus

Investment decisions are led by Managing Partner Dominique Sémon, who founded the firm in 2005. Partner Naveed Siddiqi is also a key decision-maker and has been with the firm since its early years. The small senior team structure means investment committee decisions are tightly centralized.

The firm focuses on PIPEs, pre-IPO convertible notes, and structured equity in late-stage life science companies. Merlin Nexus does not operate as a venture capital firm writing early-stage seed checks; its target window is the 12–24 months before an anticipated public listing or M&A event.

Yes. Merlin Nexus regularly participates in syndicated rounds alongside larger crossover investors such as RA Capital, Perceptive Advisors, and OrbiMed, particularly for US-bound biotech IPOs. Its value to syndicates is often the European sourcing angle for issuers that need transatlantic placement.

Merlin Nexus is an independent asset manager, not a family office. It raises committed capital from external limited partners including institutional investors, family offices, and sovereign wealth funds. The firm has no disclosed connection to a single wealth origin.

The firm maintains a dual focus on the United States and Western Europe. Known portfolio activity includes European biotech issuers cross-listing on NASDAQ, as well as US-based therapeutic companies seeking crossover financing ahead of a domestic IPO.

The firm has formed dedicated co-investment vehicles to invest pari passu with its own fund families, giving LPs direct exposure to specific late-stage healthcare positions. This suggests an institutional process for co-investment rights rather than ad hoc side letters.

Merlin Nexus is a pure healthcare investor and has no publicly disclosed activity in sectors outside biotechnology, specialty pharmaceuticals, medical devices, and diagnostics. The firm does not invest in healthcare services, health IT, or non-life-science verticals.